Register for email alerts and news feeds:
This journal | BMJ Group
rss
The most recent version of this article was published on 1 February 2008

Gut. Published Online First: 19 September 2007. doi:10.1136/gut.2007.129544
Copyright © 2007 BMJ Publishing Group Ltd & British Society of Gastroenterology.

Paper

The novel gene MIA2 acts as a tumour suppressor in hepatocellular carcinoma

Claus Hellerbrand 1*, Thomas Amann 1, Jacqueline Schlegel 1, Peter Wild 2, Frauke Bataille 1, Thilo Spruss 1, Arndt Hartmann 1 and Anja Katrin Bosserhoff 1

1 University of Regensburg, Germany
2 Departments of Pathology, University of Zurich, Switzerland

* To whom correspondence should be addressed. E-mail: claus.hellerbrand{at}klinik.uni-regensburg.de.

Accepted 5 September 2007


Abstract

Background: Melanoma Inhibitory Activity 2 (MIA2) is a novel gene of the MIA gene family. The selective expression of MIA2 in hepatocytes is controlled by hepatocyte nuclear factor (HNF) 1 binding sites in the MIA2 promotor. In contrast, in most hepatocellular carcinomas (HCC) MIA2 expression is downregulated or lost.

Aim: In this study we examined the regulation and functional role of MIA2 in hepatocancerogenesis.

Methods and results: In HCC-cell lines and tissues HNF-1 expression was lower than in primary human hepatocytes (PHH) and corresponding non-tumorous tissue, respectively, and correlated significantly with the downregulation of MIA2 expression. Re-expression of HNF-1 in HCC cells reinduced MIA2 in HCC cells to similar levels as found in PHH. Further, MIA2 was re-expressed in HCC cell lines by stable transfection, and the generated cell clones revealed a strongly reduced invasive potential and proliferation rate in vitro. In line with these findings treatment of HCC cells with recombinant MIA2 inhibited proliferation and invasion. In nude mice MIA2 re-expressing HCC cells grew significantly slower and revealed a less invasive growth pattern. Immunohistochemical analysis of a tissue microarray containing HCC and corresponding non-cancerous liver tissue of 85 patients confirmed reduced MIA2 expression in HCC. Furthermore, MIA2 negative HCC tissue showed a significantly higher Ki67 labelling index and loss of MIA2 expression correlated significantly with more advanced tumour stages.

Conclusion: This study presents MIA2 as an inhibitor of HCC growth and invasion both in vitro and in vivo, and consequently, as a tumour suppressor of HCC. Further, our findings indicate a novel mechanism, how loss of HNF-1 expression in HCC affects tumorigenicity via downregulation of MIA2.

Keywords: HCC, HNF-1, MIA2, tumour suppressor


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Relevant Article

Digest
Robin Spiller and Magnus Simren
Gut 2008 57: 1-2. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

  • Amann, T., Maegdefrau, U., Hartmann, A., Agaimy, A., Marienhagen, J., Weiss, T. S., Stoeltzing, O., Warnecke, C., Scholmerich, J., Oefner, P. J., Kreutz, M., Bosserhoff, A. K., Hellerbrand, C. (2009). GLUT1 Expression Is Increased in Hepatocellular Carcinoma and Promotes Tumorigenesis. Am. J. Pathol. 174: 1544-1552 [Abstract] [Full Text]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Cardiology Jobs

Gastroenterology Jobs